HTG Molecular Diagnostics, Inc.
HTGMQ
$0.00
$0.000.00%
OTC PK
| 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | 03/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -28.21% | -28.52% | -21.00% | 2.59% | 11.57% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -28.21% | -28.52% | -21.00% | 2.59% | 11.57% |
| Cost of Revenue | -0.64% | 5.17% | 24.80% | 32.50% | 19.78% |
| Gross Profit | -85.80% | -163.81% | -550.54% | -227.48% | -55.72% |
| SG&A Expenses | -20.32% | -8.68% | 6.73% | 8.34% | 3.85% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -12.69% | -3.37% | 13.57% | 17.11% | 9.87% |
| Operating Income | 6.30% | -8.22% | -30.69% | -23.34% | -9.18% |
| Income Before Tax | -7.27% | -26.05% | -36.14% | -28.67% | 7.28% |
| Income Tax Expenses | -37.75% | -51.34% | -61.33% | -59.46% | 74.36% |
| Earnings from Continuing Operations | -7.22% | -25.95% | -36.01% | -28.56% | 7.24% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.22% | -25.95% | -36.01% | -28.56% | 7.24% |
| EBIT | 6.30% | -8.22% | -30.69% | -23.34% | -9.18% |
| EBITDA | 5.43% | -9.26% | -33.74% | -26.58% | -12.48% |
| EPS Basic | 39.53% | 14.34% | 6.89% | 16.07% | 38.50% |
| Normalized Basic EPS | 48.67% | 27.41% | 11.03% | 18.69% | 26.66% |
| EPS Diluted | 39.53% | 14.34% | 6.89% | 16.07% | 38.50% |
| Normalized Diluted EPS | 48.67% | 27.41% | 11.03% | 18.69% | 26.66% |
| Average Basic Shares Outstanding | 106.10% | 53.82% | 48.31% | 49.52% | 45.26% |
| Average Diluted Shares Outstanding | 106.10% | 53.82% | 48.31% | 49.52% | 45.26% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |